Arvinas (NASDAQ:ARVN - Get Free Report) had its price target decreased by equities research analysts at Morgan Stanley from $48.00 to $12.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has an "equal weight" rating on the stock. Morgan Stanley's target price would suggest a potential upside of 42.35% from the stock's current price.
ARVN has been the topic of a number of other reports. Bank of America cut their price target on shares of Arvinas from $54.00 to $28.00 and set a "buy" rating on the stock in a report on Wednesday. BMO Capital Markets set a $20.00 target price on shares of Arvinas and gave the stock an "outperform" rating in a research report on Wednesday. Guggenheim lowered their price target on Arvinas from $57.00 to $32.00 and set a "buy" rating for the company in a report on Thursday. The Goldman Sachs Group cut Arvinas from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $70.00 to $15.00 in a research note on Thursday. Finally, Wells Fargo & Company set a $26.00 target price on Arvinas and gave the company an "overweight" rating in a research report on Wednesday. Five equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $37.47.
Get Our Latest Stock Analysis on Arvinas
Arvinas Stock Performance
NASDAQ ARVN traded down $0.12 on Thursday, hitting $8.43. 2,201,720 shares of the stock were exchanged, compared to its average volume of 1,696,292. Arvinas has a 52-week low of $7.91 and a 52-week high of $45.77. The firm has a market capitalization of $579.75 million, a P/E ratio of -3.04 and a beta of 1.95. The stock has a fifty day moving average price of $17.56 and a two-hundred day moving average price of $22.02.
Arvinas (NASDAQ:ARVN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same quarter last year, the company posted ($2.53) earnings per share. Sell-side analysts expect that Arvinas will post -3.81 earnings per share for the current fiscal year.
Insider Buying and Selling at Arvinas
In other Arvinas news, CEO John G. Houston sold 31,338 shares of the company's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.72, for a total transaction of $523,971.36. Following the transaction, the chief executive officer now owns 1,157,480 shares in the company, valued at approximately $19,353,065.60. This represents a 2.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Ian Taylor sold 9,020 shares of the business's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.71, for a total value of $150,724.20. Following the sale, the insider now owns 159,121 shares in the company, valued at approximately $2,658,911.91. The trade was a 5.36 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 41,572 shares of company stock worth $695,030. 5.23% of the stock is owned by insiders.
Hedge Funds Weigh In On Arvinas
A number of institutional investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new stake in shares of Arvinas in the fourth quarter worth $28,000. KBC Group NV grew its position in Arvinas by 77.0% during the 4th quarter. KBC Group NV now owns 2,885 shares of the company's stock worth $55,000 after purchasing an additional 1,255 shares during the period. Quantbot Technologies LP grew its position in Arvinas by 147.3% during the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company's stock worth $108,000 after purchasing an additional 2,601 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of Arvinas during the 4th quarter valued at about $171,000. Finally, Tema Etfs LLC acquired a new position in shares of Arvinas in the 4th quarter valued at about $227,000. 95.19% of the stock is owned by hedge funds and other institutional investors.
Arvinas Company Profile
(
Get Free Report)
Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Further Reading
Before you consider Arvinas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arvinas wasn't on the list.
While Arvinas currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
